Last reviewed · How we verify
Growth Hormones Somatropin Recombinant
Somatropin is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes.
Somatropin is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature associated with Turner syndrome.
At a glance
| Generic name | Growth Hormones Somatropin Recombinant |
|---|---|
| Also known as | Cetrorelix |
| Sponsor | ClinAmygate |
| Drug class | Growth hormone (recombinant human growth hormone) |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Somatropin mimics endogenous growth hormone by activating GH receptors on target tissues, promoting linear growth in children, increasing lean body mass, decreasing fat mass, and enhancing metabolic function. It stimulates insulin-like growth factor 1 (IGF-1) production, which mediates many of the anabolic and growth-promoting effects of growth hormone.
Approved indications
- Growth hormone deficiency in children
- Growth hormone deficiency in adults
- Short stature associated with Turner syndrome
- Chronic kidney disease-related growth failure
- Prader-Willi syndrome
Common side effects
- Injection site reactions
- Headache
- Hyperglycemia
- Fluid retention/edema
- Carpal tunnel syndrome
- Arthralgia
Key clinical trials
- Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) (PHASE4)
- Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR) (PHASE1, PHASE2)
- Growth Hormone Administration and the Human Immune System (PHASE1)
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature (PHASE3)
- Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders (PHASE3)
- A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) (PHASE1, PHASE2)
- A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) (PHASE1, PHASE2)
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Growth Hormones Somatropin Recombinant CI brief — competitive landscape report
- Growth Hormones Somatropin Recombinant updates RSS · CI watch RSS
- ClinAmygate portfolio CI